Are you aware “Dr. Reddy’s Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market”
Hyderabad, India and Princeton, NJ, USA. October 15, 2018— Dr. Reddy’s Laboratories Ltd ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA).
The Company is working towards launching the product. The Aggrenox brand and generic had U.S. sales of approximately $183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.
Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a registered trademark of Boehringer Ingelheim.